On October 30, Tempus AI fell 5.69% in Pre-Market Trading, trading at $73.0 per share, with turnover of $0.6004 million.
The move followed fresh disclosures tied to executive Eric Lefkofsky's stock sale activity, which appeared to pressure near-term market sentiment ahead of the company’s November 2 earnings release.
Recent filings showed Lefkofsky sold 108,696 common shares on October 27 at prices ranging from $67.36 to $72.31, after a separate Form 144 indicated a planned sale of 250,000 Class A common shares valued at about $16.79 million. While investors had been focusing on expectations for roughly 24.53% revenue growth this quarter and a narrower loss, the latest selling disclosures shifted attention toward insider supply and governance-related sentiment risks. Tempus AI also recently received EU IVDR Class C certification for its xR solid tumor RNA sequencing assay, but that positive catalyst was outweighed in the latest pre-market move.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments